These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 25530915

  • 1. FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimer's Disease.
    Murray J, Tsui WH, Li Y, McHugh P, Williams S, Cummings M, Pirraglia E, Solnes L, Osorio R, Glodzik L, Vallabhajosula S, Drzezga A, Minoshima S, de Leon MJ, Mosconi L.
    Adv J Mol Imaging; 2014 Apr; 4(2):15-26. PubMed ID: 25530915
    [Abstract] [Full Text] [Related]

  • 2. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.
    Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, Murray J, Scheinin N, Någren K, Williams S, Glodzik L, De Santi S, Vallabhajosula S, de Leon MJ.
    Proc Natl Acad Sci U S A; 2010 Mar 30; 107(13):5949-54. PubMed ID: 20231448
    [Abstract] [Full Text] [Related]

  • 3. Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD.
    Mosconi L, Murray J, Tsui WH, Li Y, Spector N, Goldowsky A, Williams S, Osorio R, McHugh P, Glodzik L, Vallabhajosula S, de Leon MJ.
    Neurology; 2014 Mar 04; 82(9):752-60. PubMed ID: 24523481
    [Abstract] [Full Text] [Related]

  • 4. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.
    Mosconi L, Rinne JO, Tsui WH, Murray J, Li Y, Glodzik L, McHugh P, Williams S, Cummings M, Pirraglia E, Goldsmith SJ, Vallabhajosula S, Scheinin N, Viljanen T, Någren K, de Leon MJ.
    Neurobiol Aging; 2013 Jan 04; 34(1):22-34. PubMed ID: 22503001
    [Abstract] [Full Text] [Related]

  • 5. Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism.
    Yi D, Lee Y, Byun MS, Lee JH, Ko K, Sohn BK, Choe YM, Choi HJ, Baek H, Sohn CH, Kim YK, Lee DY, KBASE research group.
    Alzheimers Res Ther; 2018 Aug 23; 10(1):84. PubMed ID: 30134963
    [Abstract] [Full Text] [Related]

  • 6. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease.
    Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K, Pirraglia E, Tsui W, De Santi S, de Leon MJ.
    Neurology; 2009 Feb 10; 72(6):513-20. PubMed ID: 19005175
    [Abstract] [Full Text] [Related]

  • 7. Physical Activity, Mediterranean Diet and Biomarkers-Assessed Risk of Alzheimer's: A Multi-Modality Brain Imaging Study.
    Matthews DC, Davies M, Murray J, Williams S, Tsui WH, Li Y, Andrews RD, Lukic A, McHugh P, Vallabhajosula S, de Leon MJ, Mosconi L.
    Adv J Mol Imaging; 2014 Oct 10; 4(4):43-57. PubMed ID: 25599008
    [Abstract] [Full Text] [Related]

  • 8. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease.
    Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, Ackermann U, Saunder T, Tochon-Danguy H, Jones G, Smith C, O'Keefe G, Masters CL, Rowe CC.
    J Nucl Med; 2007 Apr 10; 48(4):547-52. PubMed ID: 17401090
    [Abstract] [Full Text] [Related]

  • 9. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.
    Tiepolt S, Hesse S, Patt M, Luthardt J, Schroeter ML, Hoffmann KT, Weise D, Gertz HJ, Sabri O, Barthel H.
    Eur J Nucl Med Mol Imaging; 2016 Aug 10; 43(9):1700-9. PubMed ID: 27026271
    [Abstract] [Full Text] [Related]

  • 10. Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study.
    Mosconi L, Murray J, Davies M, Williams S, Pirraglia E, Spector N, Tsui WH, Li Y, Butler T, Osorio RS, Glodzik L, Vallabhajosula S, McHugh P, Marmar CR, de Leon MJ.
    BMJ Open; 2014 Jun 24; 4(6):e004850. PubMed ID: 24961717
    [Abstract] [Full Text] [Related]

  • 11. Amyloid load but not regional glucose metabolism predicts conversion to Alzheimer's dementia in a memory clinic population.
    Frings L, Hellwig S, Bormann T, Spehl TS, Buchert R, Meyer PT.
    Eur J Nucl Med Mol Imaging; 2018 Jul 24; 45(8):1442-1448. PubMed ID: 29546632
    [Abstract] [Full Text] [Related]

  • 12. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, McDade E, Aizenstein HJ, Klunk WE, Mathis CA.
    Neuroimage Clin; 2015 Jul 24; 9():592-8. PubMed ID: 26640770
    [Abstract] [Full Text] [Related]

  • 13. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.
    Rabinovici GD, Furst AJ, O'Neil JP, Racine CA, Mormino EC, Baker SL, Chetty S, Patel P, Pagliaro TA, Klunk WE, Mathis CA, Rosen HJ, Miller BL, Jagust WJ.
    Neurology; 2007 Apr 10; 68(15):1205-12. PubMed ID: 17420404
    [Abstract] [Full Text] [Related]

  • 14. Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals.
    Berti V, Murray J, Davies M, Spector N, Tsui WH, Li Y, Williams S, Pirraglia E, Vallabhajosula S, McHugh P, Pupi A, de Leon MJ, Mosconi L.
    J Nutr Health Aging; 2015 Apr 10; 19(4):413-23. PubMed ID: 25809805
    [Abstract] [Full Text] [Related]

  • 15. Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting.
    Banzo I, Jiménez-Bonilla J, Ortega-Nava F, Quirce R, Martínez-Rodríguez I, de Arcocha-Torres M, Rodríguez E, Vázquez JL, Sánchez PJ, Martínez-Amador N, Ibañez-Bravo S, Carril JM.
    Nucl Med Commun; 2014 Mar 10; 35(3):238-44. PubMed ID: 24240196
    [Abstract] [Full Text] [Related]

  • 16. Structural brain changes in normal individuals with a maternal history of Alzheimer's.
    Berti V, Mosconi L, Glodzik L, Li Y, Murray J, De Santi S, Pupi A, Tsui W, De Leon MJ.
    Neurobiol Aging; 2011 Dec 10; 32(12):2325.e17-26. PubMed ID: 21316814
    [Abstract] [Full Text] [Related]

  • 17. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
    Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Jonasson M, Eriksson J, Lubberink M, Almkvist O, Wall A, Antoni G, Nordberg A.
    Eur J Nucl Med Mol Imaging; 2016 Aug 10; 43(9):1686-99. PubMed ID: 26996778
    [Abstract] [Full Text] [Related]

  • 18. Comparison of [18F]Flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals.
    Lowe VJ, Lundt E, Knopman D, Senjem ML, Gunter JL, Schwarz CG, Kemp BJ, Jack CR, Petersen RC.
    Neuroimage Clin; 2017 Aug 10; 16():295-302. PubMed ID: 28856092
    [Abstract] [Full Text] [Related]

  • 19. Statistical Parametric Mapping in Amyloid Positron Emission Tomography.
    Smith NM, Ford JN, Haghdel A, Glodzik L, Li Y, D'Angelo D, RoyChoudhury A, Wang X, Blennow K, de Leon MJ, Ivanidze J.
    Front Aging Neurosci; 2022 Aug 10; 14():849932. PubMed ID: 35547630
    [Abstract] [Full Text] [Related]

  • 20. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T, Wutz C, Alexopoulos P, Drzezga A, Förster S, Förstl H, Goldhardt O, Ortner M, Sorg C, Kurz A.
    J Nucl Med; 2016 Feb 10; 57(2):204-7. PubMed ID: 26585056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.